What the FDA labels say about taking them together
Fosamprenavir and salmeterol
Fosamprenavir's FDA label of September 15, 2023 names salmeterol in its drug interactions section; the salmeterol label PlainMeds reads does not name fosamprenavir. The fosamprenavir label: “Concurrent administration of salmeterol with fosamprenavir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation …”
Check it at the source: the fosamprenavir FDA label on DailyMed (effective September 15, 2023, Mylan Pharmaceuticals Inc.); the salmeterol FDA label on DailyMed (effective October 10, 2022, GlaxoSmithKline LLC).
What does the fosamprenavir label say about salmeterol?
Fosamprenavir label, drug interactionsConcomitant Drug Class/Drug Name: Inhaled beta-agonist: Salmeterol; Effect on Concentration of Amprenavir or Concomitant Drug: ↑ Salmeterol; Clinical Comment: Concurrent administration of salmeterol with fosamprenavir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.
Source: FDA drug label (Fosamprenavir Calcium), Mylan Pharmaceuticals Inc., effective September 15, 2023 (SPL set 3a1424d8-844c-4e24-9ebd-b2c2b61b61a3), via openFDA; the full label on DailyMed
What does the salmeterol label say about fosamprenavir?
Salmeterol's label (effective October 10, 2022) does not name fosamprenavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (SEREVENT DISKUS), GlaxoSmithKline LLC, effective October 10, 2022 (SPL set 12d9728e-6b5c-4aee-bfb0-745e542ed2e4), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fosamprenavir | Salmeterol | |
|---|---|---|
| Labeled for | HIV | Asthma, COPD |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $6.74 per unit 50 mcg |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once